These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 22516539

  • 1. [Immunotherapy: an emerging strategies against prostate castration resistant cancer].
    Mansi L, Thiery-Vuillemin A, Kalbacher E, Nguyen T, Maurina T, Nallet J, Kim S, Borg C, Kleinclauss F, Pivot X, Adotevi O.
    Bull Cancer; 2012 Jul; 99 Suppl 1():S57-65. PubMed ID: 22516539
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG, Gelpi-Hammerschmidt F, Kundavram C.
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
    Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.
    Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
    Lü C, Williams AK, Chalasani V, Martínez CH, Chin J.
    Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P.
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [Abstract] [Full Text] [Related]

  • 11. Current vaccination strategies for prostate cancer.
    Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [Abstract] [Full Text] [Related]

  • 12. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX, Fong L, Small EJ.
    Expert Rev Vaccines; 2015 Feb; 14(12):1529-41. PubMed ID: 26488270
    [Abstract] [Full Text] [Related]

  • 13. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
    Mulders PF, De Santis M, Powles T, Fizazi K.
    Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Integration of immunotherapy into the management of advanced prostate cancer.
    Kantoff P, Higano CS.
    Urol Oncol; 2012 Jun; 30(5 Suppl):S41-7. PubMed ID: 23040162
    [Abstract] [Full Text] [Related]

  • 17. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
    Quinn DI, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM.
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A comprehensive review of immunotherapies in prostate cancer.
    Maia MC, Hansen AR.
    Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
    [Abstract] [Full Text] [Related]

  • 20. Combining immunotherapies for the treatment of prostate cancer.
    Redman JM, Gulley JL, Madan RA.
    Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.